Analysts predict that Opko Health Inc. (NASDAQ:OPK) will announce sales of $254.10 million for the current quarter, Zacks reports. Three analysts have provided estimates for Opko Health’s earnings, with the highest sales estimate coming in at $267.50 million and the lowest estimate coming in at $239.10 million. Opko Health reported sales of $193.70 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 31.2%. The business is scheduled to report its next quarterly earnings results on Thursday, March 7th.
On average, analysts expect that Opko Health will report full-year sales of $1.03 billion for the current financial year, with estimates ranging from $1.01 billion to $1.05 billion. For the next year, analysts expect that the company will post sales of $1.05 billion, with estimates ranging from $1.03 billion to $1.09 billion. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Opko Health.
Opko Health (NASDAQ:OPK) last issued its quarterly earnings data on Friday, November 9th. The biotechnology company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.03. Opko Health had a negative net margin of 30.24% and a negative return on equity of 8.68%. The firm had revenue of $250.00 million for the quarter, compared to analyst estimates of $264.04 million. During the same period in the prior year, the business posted ($0.08) EPS. The business’s revenue for the quarter was up 1.6% compared to the same quarter last year.
Several equities analysts have recently commented on the stock. BidaskClub upgraded shares of Opko Health from a “buy” rating to a “strong-buy” rating in a report on Friday, August 3rd. Cantor Fitzgerald restated a “buy” rating and issued a $20.00 price objective on shares of Opko Health in a report on Tuesday, August 7th. ValuEngine upgraded shares of Opko Health from a “strong sell” rating to a “sell” rating in a report on Thursday, August 2nd. Finally, Barrington Research restated a “buy” rating and issued a $7.00 price objective on shares of Opko Health in a report on Monday, November 12th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $9.69.
In related news, CEO Phillip Md Et Al Frost acquired 10,000 shares of the firm’s stock in a transaction dated Friday, September 7th. The shares were purchased at an average cost of $5.57 per share, for a total transaction of $55,700.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 42.74% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in OPK. RPg Family Wealth Advisory LLC increased its position in shares of Opko Health by 74.3% in the 2nd quarter. RPg Family Wealth Advisory LLC now owns 31,080 shares of the biotechnology company’s stock valued at $146,000 after purchasing an additional 13,250 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Opko Health by 4.3% in the 3rd quarter. Wells Fargo & Company MN now owns 337,868 shares of the biotechnology company’s stock valued at $1,169,000 after purchasing an additional 13,905 shares during the last quarter. Strs Ohio increased its position in shares of Opko Health by 20.5% in the 3rd quarter. Strs Ohio now owns 88,600 shares of the biotechnology company’s stock valued at $306,000 after purchasing an additional 15,100 shares during the last quarter. RK Asset Management LLC increased its position in shares of Opko Health by 1.8% in the 3rd quarter. RK Asset Management LLC now owns 1,044,893 shares of the biotechnology company’s stock valued at $3,615,000 after purchasing an additional 18,875 shares during the last quarter. Finally, Rhumbline Advisers increased its position in shares of Opko Health by 6.1% in the 2nd quarter. Rhumbline Advisers now owns 337,168 shares of the biotechnology company’s stock valued at $1,585,000 after purchasing an additional 19,316 shares during the last quarter. Institutional investors own 26.99% of the company’s stock.
Shares of OPK stock opened at $3.63 on Friday. The company has a current ratio of 0.91, a quick ratio of 0.78 and a debt-to-equity ratio of 0.03. Opko Health has a one year low of $2.66 and a one year high of $6.40. The company has a market capitalization of $1.83 billion, a PE ratio of -12.52 and a beta of 1.89.
Opko Health Company Profile
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
Featured Article: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.